Articles by Melanie Sena - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Melanie Sena

Melanie Sena


Melanie Sena is community editor of Pharmaceutical Technology.

Articles
CPI Announce Investment into Biologics Factory of the Future
July 23, 2014

CPI invests $34 million to develop a Biologics Factory of the Future due to open in 2017.

MedImmune Collaborates With Advaxis on Immunotherapies
July 22, 2014

MedImmune and Advaxis partner on immuno-oncology combination clinical trial.

Novasep Passes FDA Inspections on Two Sites
July 22, 2014

Novasep gains approval from FDA to produce new molecular entity for US market.

AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014

AbbVie's relocation to Ireland following Shire's acquisition could lower its annual tax expense by as much as 7% over the next 15 years.

Novartis to License Google "Smart Lens" Technology
July 18, 2014

Alcon enters agreement with Google to in-license its "smart lens" Ttechnology for all ocular medical uses.

AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014

AstraZeneca releases designs for its new Global R&D center and corporate headquarters in Cambridge, UK.

CPhI Announces 2014 Expert Panel and Report
July 18, 2014

CPhI 2014 panel additions to provide global insights from the contract services sector.

Pfizer to Acquire InnoPharma
July 16, 2014

Pfizer will acquire InnoPharma for $225 million.

US Falls Behind in Facilitating New Antibiotics Pipeline
July 15, 2014

GlobalData report reveals the US trails Europe in strengthening its stagnant antibiotics pipeline.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here